enzyme

IDH2

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about IDH2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

298Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

1Experiments

2Debates

Summary

IDH2 is an entity related to neurodegeneration research. Key relationships include: therapeutic target, implicated in, associated with. Associated with AD, ADH, ALI. Connected to 119 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	IDH2
Chromosome	15q26.1
Protein Type	Gene
Target Class	Enzyme
Function	Isocitrate dehydrogenase 2 (IDH2) is a mitochondrial enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), producing NADPH in the mitochondrial matrix.
Mechanism of Action	Small molecule inhibitor of mutant IDH2 enzyme activity
Subcellular Localization	the mitochondrial matrix, where it plays essential roles in both energy production and cellular redox homeostasis. The e
Druggability	High (0.90)
Clinical Stage	Approved
Pathways	Calcium Signaling, Circadian Rhythm, Complement, Epigenetic, Glycolysis
UniProt ID	P00342
GeneCards	IDH2
Human Protein Atlas	IDH2
Associated Diseases	AD, ADH, ALI, Als, AMI, ARM
Known Drugs/Compounds	GEMCITABINE
Interactions	AIFM1, ALZHEIMER, ALZHEIMER'S DISEASE, AMPK, AMYLOID, AMYLOID-Β PLAQUES
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Grid Cell-Specific Metabolic Reprogramming via IDH
KG Connections	297 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — IDH2 Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

5I95 — X-ray / Cryo-EM

🔮 AI Predicted Structure

P00342 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

idh2

gene · 644 words

→

Pathway Diagram

graph TD
    IDH2["IDH2"] -->|"associated"| HIF_1_["HIF-1alpha"]
    IDH2["IDH2"] -->|"contributes to"| Gemcitabine_Resistance["Gemcitabine Resistance"]
    IDH2["IDH2"] -->|"causes"| Cisplatin_Resistance["Cisplatin Resistance"]
    IDH2["IDH2"] -->|"activates"| Pentose_Phosphate_Pathway["Pentose Phosphate Pathway"]
    IDH2["IDH2"] -->|"regulates"| NADPH_Production["NADPH Production"]
    IDH2["IDH2"] -->|"regulates"| Glutathione_Production["Glutathione Production"]
    h_57862f8a["h-57862f8a"] -->|"targets"| IDH2["IDH2"]
    IDH1["IDH1"] -.->|"inhibits"| IDH2["IDH2"]
    TIGAR["TIGAR"] -->|"therapeutic target"| IDH2["IDH2"]
    IDH1_1["IDH1"] -->|"associated"| IDH2["IDH2"]
    style IDH2 fill:#006494,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (212)

Target	Relation	Type	Str
Isocitrate to α-Ketoglutarate Conversion	catalyzes	process	0.98
GLIOMA	associated_with	entity	0.98
ASTROCYTOMA	associated_with	entity	0.95
ENZYMATIC ACTIVITY	regulates	entity	0.95
HIF1A	associated_with	entity	0.95
THERAPEUTIC_TARGET	therapeutic_target	entity	0.95
ALPHA-KETOGLUTARATE	associated_with	entity	0.95
urothelial carcinoma chemoresistance	promotes	phenotype	0.95
Isocitrate To α-Ketoglutarate Conversion	catalyzes	process	0.95
Chemoresistance	promotes	phenotype	0.95
Isocitrate	associated_with	compound	0.95
Nadp+-Dependent Isocitrate Dehydrogenase	involved_in	enzyme	0.92
Glioblastoma	associated_with	disease	0.92
Aerobic Glycolysis	upregulates	pathway	0.90
Urothelial Carcinoma	therapeutic_target	disease	0.90
GLIOMA	mutated_in	disease	0.90
Pentose Phosphate Pathway	upregulates	pathway	0.90
Glioma	biomarker_for	disease	0.90
gliomas	associated_with	disease	0.90
AEROBIC GLYCOLYSIS	upregulates	entity	0.90
PENTOSE PHOSPHATE PATHWAY	upregulates	entity	0.90
NADPH	upregulates	entity	0.90
GLUTATHIONE	upregulates	entity	0.90
NADH	associated_with	entity	0.90
NADPH	associated_with	entity	0.90
BRAIN TUMOURS	associated_with	entity	0.90
Urothelial Carcinoma	associated_with	disease	0.90
Patient Survival	protects_against	phenotype	0.85
Gene Expression	regulates	process	0.85
Cddp Resistance	promotes	phenotype	0.85
Glutamine Metabolism	upregulates	pathway	0.85
Nadph Production	upregulates	process	0.85
REDOX BALANCE	associated_with	entity	0.85
OXIDATIVE STRESS	protects_against	entity	0.85
GLUTAMINE METABOLISM	modulates	entity	0.85
ORGAN PHYSIOLOGY	regulates	entity	0.85
glutamine metabolism	associated_with	pathway	0.85
Chemoresistance	associated_with	phenotype	0.80
HIF-1α	stabilizes	protein	0.80
CTPS1	regulates	gene	0.80
Metabolic Rewiring	involved_in	process	0.80
Metabolic Reprogramming	associated_with	biological_process	0.80
NEURODEGENERATION	associated_with	entity	0.80
neurodegeneration	associated_with	disease	0.80
Neurodegeneration	contributes_to	disease	0.75
CANCER	stabilizes	disease	0.70
OXIDATIVE STRESS	treats	phenotype	0.70
NEURONS	activates	cell_type	0.70
OXIDATIVE STRESS	activates	phenotype	0.70
Grid Cell-Specific Metabolic Reprogramming via IDH	regulates	mechanism	0.70

Incoming (86)

Source	Relation	Type	Str
h-57862f8a	targets_gene	hypothesis	0.90
TIGAR	associated_with	entity	0.85
TKT	associated_with	entity	0.85
CTPS1	associated_with	entity	0.85
IDH1	interacts_with	entity	0.85
h-57862f8a	targets	hypothesis	0.80
NEURON	causes	cell_type	0.70
HIF	promotes	gene	0.60
ALZHEIMER	activates	gene	0.60
NEURODEGENERATION	regulates	gene	0.60
CIRCADIAN RHYTHM	therapeutic_target	gene	0.60
IDH1	inhibits	gene	0.60
TIGAR	therapeutic_target	gene	0.60
IDH1	associated_with	gene	0.60
TKT	therapeutic_target	gene	0.60
GAIN	activates	gene	0.60
CD47	therapeutic_target	gene	0.60
CD33	therapeutic_target	gene	0.60
IDH1	regulates	gene	0.60
MCL1	therapeutic_target	gene	0.60
NPM1	associated_with	gene	0.60
TP53	associated_with	gene	0.60
TET2	associated_with	gene	0.60
DNMT3A	associated_with	gene	0.60
NRAS	associated_with	gene	0.60
IDH1	therapeutic_target	gene	0.60
CTPS1	regulates	gene	0.60
AIFM1	interacts_with	gene	0.60
AIFM1	activates	gene	0.60
PER	therapeutic_target	gene	0.60
ACHE	therapeutic_target	gene	0.60
CANCER	therapeutic_target	gene	0.60
TP53	therapeutic_target	gene	0.60
SCN5A	therapeutic_target	gene	0.60
IL1B	therapeutic_target	gene	0.60
KCNQ1	therapeutic_target	gene	0.60
TNF	therapeutic_target	gene	0.60
CALM1	therapeutic_target	gene	0.60
LMNA	therapeutic_target	gene	0.60
HRAS	therapeutic_target	gene	0.60
DRD2	therapeutic_target	gene	0.60
PPARG	therapeutic_target	gene	0.60
KCNH2	therapeutic_target	gene	0.60
TKT	regulates	gene	0.60
CPT2	activates	gene	0.60
OXIDATIVE STRESS	regulates	gene	0.60
glycolysis	activates	pathway	0.60
NRF2	activates	gene	0.60
GAIN	expressed_in	gene	0.60
AND	therapeutic_target	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem	0.646	neurodegeneration	Selective vulnerability of entorhinal co

Mentioning Analyses (2)

Scientific analyses that reference this entity

What mechanisms explain how IDH1/IDH2 mutations with reduced enzymatic activity

neurodegeneration | 2026-04-13 | 0 hypotheses

Selective vulnerability of entorhinal cortex layer II neurons in AD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.696

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Clinical outcome analysis based on IDH mutation status	clinical	gliomas	0.850	0.00	human patients	proposed	N/A

Related Papers (16)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
IDH2 stabilizes HIF-1α-induced metabolic reprogramming and promotes chemoresista [PMID:36637036]	Shigeta K, Hasegawa M, Hishiki T, Naito	EMBO J	2023	1
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydr [PMID:31131326]	Tommasini-Ghelfi S, Murnan K, Kouri FM,	Sci Adv	2019	1
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcino [PMID:28622513]	Cancer Genome Atlas Research Network. El	Cell	2017	1
Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. [PMID:25944653]	Brandner S, von Deimling A	Neuropathol Appl Neurobiol	2015	1
IDH1 and IDH2 mutations in gliomas. [PMID:19228619]	Yan H, Parsons DW, Jin G, McLendon R, Ra	N Engl J Med	2009	1
Advancements in targeted therapies for acute myeloid leukemia. [PMID:41576755]	Connor MP, Barsouk A, Elghawy O, Lai C	Curr Opin Pharmacol	2026	0
ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clea [PMID:41637546]	Koh J, Liao C, Ng MSW, Hong JH, Heng HL	Cancer Res	2026	0
Serine mediates protection against calcium oxalate nephrolithiasis by attenuatin [PMID:41930872]	Yan X, Li G, Wang Z, Li C, Shi Y et al.	Int Immunopharmacol	2026	0
Chemical Proteomics Reveals Human Off-Targets of Fluoroquinolone Induced Mitocho [PMID:39964703]	["Reinhardt T", "El Harraoui Y", "Rothem	Angewandte Chemie (Internation	2025	0
Succinate-loaded tumor cell-derived microparticles reprogram tumor-associated ma [PMID:40203081]	Lu S, Li J, Li Y, Liu S, Liu Y, Liang Y,	Science translational medicine	2025	0
Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restrainin [PMID:38171332]	Si X, Shao M, Teng X, Huang Y, Meng Y, W	Cell metabolism	2024	0
Metabolic dysregulation and emerging therapeutical targets for hepatocellular ca [PMID:35256934]	Du D, Liu C, Qin M, Zhang X, Xi T, Yuan	Acta pharmaceutica Sinica. B	2022	0
Opportunities and obstacles for deep learning in biology and medicine. [PMID:29618526]	["Ching T", "Himmelstein D", "Beaulieu-J	Journal of the Royal Society,	2018	0
Autophagy mediates degradation of nuclear lamina. [PMID:26524528]	["Dou Z", "Xu C", "Donahue G", "Shimi T"	Nature	2015	0
Loop-based multiple heart-cutting two-dimensional liquid chromatography for targ [PMID:25897943]	["Pursch M", "Buckenmaier S"]	Analytical chemistry	2015	0
Methanesulfonic acid sodium salt protects retina from acute light damage in mice [PMID:22882854]	Wang HY, Gu Q, Xu X	Chinese medical journal	2012	0

Debates (2)

Multi-agent debates referencing this entity

The abstract shows that IDH mutations reduce protein enzymatic activity yet para

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Why do entorhinal cortex layer II stellate neurons die first in AD? Their unique

closed · Rounds: 6 · Score: 0.95 · 2026-04-10